Coya Therapeutics (COYA) Expected to Announce Earnings on Wednesday

Coya Therapeutics (NASDAQ:COYA) is anticipated to announce its Q3 2026 resultson Wednesday, November 11th. Analysts expect the company to announce earnings of ($0.35) per share and revenue of $0.11 million for the quarter. Parties are encouraged to explore the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 9:30 AM ET.

Coya Therapeutics (NASDAQ:COYA) last released its quarterly earnings results on Tuesday, August 11th. The company reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.07. Coya Therapeutics had a negative return on equity of 52.05% and a negative net margin of 270.22%. The company had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.13 million. On average, analysts expect Coya Therapeutics to post ($1.34) EPS for the current fiscal year and ($1.94) EPS for the next fiscal year.

Coya Therapeutics Price Performance

Shares of COYA stock opened at $3.25 on Wednesday. Coya Therapeutics has a 12-month low of $3.03 and a 12-month high of $6.62. The firm has a market capitalization of $76.25 million, a price-to-earnings ratio of -3.04 and a beta of 0.70. The business has a 50 day simple moving average of $4.54 and a 200 day simple moving average of $4.63.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. Chardan Capital reiterated a “buy” rating and set a $14.00 price target on shares of Coya Therapeutics in a research report on Wednesday, August 12th. Roth Capital reissued a “buy” rating and set a $12.00 price target on shares of Coya Therapeutics in a report on Monday, August 24th. HC Wainwright restated a “buy” rating on shares of Coya Therapeutics in a research note on Friday, September 25th. BTIG Research reaffirmed a “buy” rating and issued a $16.00 price objective on shares of Coya Therapeutics in a report on Tuesday, September 15th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research report on Thursday, October 15th. Six equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $15.33.

About Coya Therapeutics

Coya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. Tregs help regulate immune activity, and the company is studying their potential to address neurodegenerative diseases and other conditions involving inflammation and immune dysfunction.

The company’s lead investigational program, COYA 101, is an autologous Treg cell therapy being evaluated for amyotrophic lateral sclerosis (ALS). The treatment is designed to use a patient’s own regulatory T cells, which are expanded and functionally enhanced outside the body before being administered.